We are live on ! Find out more
BCM

Bridgeway Capital Management Portfolio holdings

AUM $4.97B
1-Year Est. Return 44.96%
This Fund
S&P 500
This Quarter Est. Return
-11.29%
1 Year Est. Return
+44.96%
3 Year Est. Return
+114.45%
5 Year Est. Return
+175.29%
10 Year Est. Return
+704.01%
AUM
$4.38B
AUM Growth
-$799M
Cap. Flow
-$109M
Cap. Flow %
-2.49%
Top 10 Hldgs %
5.78%
Holding
1,425
New
121
Increased
257
Reduced
318
Closed
105

Top Buys

Rank Stock Value
1
CRL icon
Charles River Laboratories
CRL
+$21M
2
NUE icon
Nucor
NUE
+$15.4M
3
GIS icon
General Mills
GIS
+$13M
4
DOW icon
Dow Inc
DOW
+$11.2M
5
OXY icon
Occidental Petroleum
OXY
+$10.3M

Top Sells

Rank Stock Value
1
AR icon
Antero Resources
AR
+$17.7M
2
CL icon
Colgate-Palmolive
CL
+$15.8M
3
NSC icon
Norfolk Southern
NSC
+$15.4M
4
WAT icon
Waters Corp
WAT
+$11M
5
NTAP icon
NetApp
NTAP
+$10.6M

Sector Composition

Rank Sector Weight
1 Financials 27.17%
2 Energy 10.91%
3 Industrials 10.83%
4 Consumer Discretionary 9.97%
5 Technology 9.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PAYS icon
1101
Paysign
PAYS
$693M
$189K ﹤0.01%
124,100
+6,200
+5% +$10.3K
ZYNE
1102
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$189K ﹤0.01%
165,900
-10,000
-6% -$12.7K
AAOI icon
1103
Applied Optoelectronics
AAOI
$9.97B
$188K ﹤0.01%
121,500
+46,500
+62% +$114K
TARA icon
1104
Protara Therapeutics
TARA
$230M
$188K ﹤0.01%
64,000
– –
VIP
1105
Vulcan Infrastructure and Power Inc. Class A Common Stock
VIP
$37.5M
$187K ﹤0.01%
7,380
+2,500
+51% +$141K
OKUR
1106
OnKure Therapeutics
OKUR
$168M
$186K ﹤0.01%
7,000
-3,000
-30% -$69.8K
IMDX
1107
Insight Molecular Diagnostics
IMDX
$155M
$185K ﹤0.01%
10,265
– –
NCMI icon
1108
National CineMedia
NCMI
$378M
$183K ﹤0.01%
20,000
-5,000
-20% -$84.5K
SLDB icon
1109
Solid Biosciences
SLDB
$857M
$182K ﹤0.01%
19,687
-6,666
-25% -$69.3K
RRGB icon
1110
Red Robin
RRGB
$156M
$181K ﹤0.01%
22,600
– –
ZVO
1111
DELISTED
Zovio Inc. Common Stock
ZVO
$181K ﹤0.01%
186,700
-152,000
-45% -$124K
XTNT icon
1112
Xtant Medical Holdings
XTNT
$62.1M
$180K ﹤0.01%
347,000
– –
SDPI
1113
DELISTED
Superior Drilling Products Inc.
SDPI
$179K ﹤0.01%
180,900
– –
SHPW
1114
DELISTED
Shapeways Holdings, Inc. Common Stock
SHPW
$179K ﹤0.01%
19,161
-1,089
-5% -$15.3K
BCEL
1115
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$179K ﹤0.01%
100,000
– –
CGBD icon
1116
Carlyle Secured Lending
CGBD
$741M
$178K ﹤0.01%
14,000
-11,000
-44% -$154K
DNTH icon
1117
Dianthus Therapeutics
DNTH
$6.15B
$177K ﹤0.01%
9,200
– –
MPU icon
1118
Mega Matrix
MPU
$14M
$177K ﹤0.01%
130,345
-28,155
-18% -$38.4K
NNVC icon
1119
NanoViricides
NNVC
$35.7M
$177K ﹤0.01%
94,039
– –
ELUT icon
1120
Elutia
ELUT
$38.9M
$176K ﹤0.01%
24,900
– –
PLX icon
1121
Protalix BioTherapeutics
PLX
$197M
$173K ﹤0.01%
158,790
+130,000
+452% +$152K
OYST
1122
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$173K ﹤0.01%
+40,000
New +$227K
CVRX icon
1123
CVRx
CVRX
$158M
$172K ﹤0.01%
28,595
+13,595
+91% +$78.2K
XBIT icon
1124
XBiotech
XBIT
$69.5M
$172K ﹤0.01%
+30,500
New +$205K
ICD
1125
DELISTED
Independence Contract Drilling, Inc.
ICD
$172K ﹤0.01%
55,000
+25,000
+83% +$96.9K
43 44
45
46 47

Similar funds

SNT
SIG North Trading Bala Cynwyd, Pennsylvania $4.98B AUM 36.24% 1-Year Est. Return
MA
Marshfield Associates Washington, District of Columbia $4.99B AUM 1.59% 1-Year Est. Return
FFB
First Financial Bankshares Abilene, Texas $4.95B AUM 25.06% 1-Year Est. Return
AM
Atreides Management Boston, Massachusetts $5B AUM 78.34% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
SMFG
Sumitomo Mitsui Financial Group Tokyo, Japan $4.94B AUM 1.39% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return

Bridgeway Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Bridgeway Capital Management held 1,425 positions worth $4.38B, down 15% from $5.17B the previous quarter. Its ten largest holdings account for 5.8% of the portfolio.

Bridgeway Capital Management's Q2 2022 filing shows 121 new, 257 increased, 318 reduced and 105 closed positions. Its largest new stake was Charles River Laboratories: 86,100 shares worth $18.4M. The largest sale was Antero Resources, an estimated $17.7M.

By sector, the portfolio is most concentrated in Financials at 27% of assets, up from 25% a quarter earlier, followed by Energy and Industrials.

  • Bridgeway Capital Management's largest Q2 2022 buy was Charles River Laboratories: 86,100 shares worth $18.4M.
  • Bridgeway Capital Management added most to Nucor in Q2 2022, an estimated $15.4M increase.
  • Bridgeway Capital Management's biggest Q2 2022 reduction was Antero Resources, cutting an estimated $17.7M.
  • Bridgeway Capital Management fully exited Colgate-Palmolive in Q2 2022, selling an estimated $15.8M.
  • Bridgeway Capital Management's ten largest holdings make up 5.8% of its $4.38B portfolio in Q2 2022.
  • Bridgeway Capital Management opened 121 new positions and closed 105 in Q2 2022.
  • Bridgeway Capital Management's portfolio value fell 15% quarter-over-quarter to $4.38B.

Based on Bridgeway Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.